Fig. 9.

(a) (top- first study) and (b) (bottom- second study): Tumour volumes for female CD-1 mice bearing intracranial U-87 MG tumours following treatment with lomustine formulations. QLOM = MET lomustine (13 mg kg⁻¹ per day, 2.6 mg mL⁻¹, dose volume = ≈ 200 μL, LOM-ETOH = ethanolic lomustine (1.2 mg kg⁻¹ per day, 0.18 mg mL⁻¹, dose volume = ≈ 200 μL), CONTROL = untreated control animals. * = Significantly different from MET lomustine (13 mg kg⁻¹) formulation treated animals.